Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Meyers, MD, PhD
Syndax Pharmaceuticals
Study Director - Ursula Matulonis, MD
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- H. Lee Moffitt Cancer Center and Research
Tampa, Florida, United States
- Florida Cancer Specialist East Region (scri Affiliate)
West Palm Beach, Florida, United States
- University of Chicago
Chicago, Illinois, United States
- Greater Baltimore Medical Center
Baltimore, Maryland, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, Maryland, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Hca Midwest Health (scri Affiliate)
Kansas City, Missouri, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- University of Virginia
Charlottesville, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Dec 2016
- Primary completion
- 21 Feb 2019
- Completion
- 21 Apr 2021
- Last update posted
- 10 Jan 2024
- Registered enrollment
- 140
- Registry id
- NCT02915523
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.